Thanks fat.
"In the proposed acquisition it's States
Total A$3 million up-front licence fee, and up to A$1 million in milestone payments based on clinical trial recruitment"
So who are we potentially doing this clinical trial recruitment with? If we dig deeper and go back to another few announcements when the excellent COVID data was released it states the following:
"ResApp will initially target use in settings where frequent COVID-19 testing is required, such as
employee, healthcare worker and student screening, travel, sports, entertainment, and aged care."
So perhaps will strike a partnership in one of these areas?!
Also the follow is stated..
" ResApp intends to submit the results for publication in a peer-reviewed journal in the coming weeks."
" We intend to accelerate commercialisation by immediately
engaging with regulators globally and we have already commenced discussions with global health and technology companies with the goal of rapidly bringing this product to market"
So can't be long now...
Cheers
Red bar
rap chart, page-4513
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #